Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
NEW YORK, May 01, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of INSYS Therapeutics, Inc. (NASDAQ:INSY) who purchased shares between February 23, 2016 and March 15, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS public statements were materially false and misleading at all relevant times.
Shareholders have until May 16, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/insys-therapeutics-inc?wire=1.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
